Cart
sales@molnova.com
GSK3a-IN-38
CAS No. 1062138-03-7
GSK3a-IN-38( —— )
Catalog No. M37037 CAS No. 1062138-03-7
GSK3a-IN-38 is a novel small molecule compound that has inhibitory effects on GSK-3a.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 34 | In Stock |
|
| 10MG | 52 | In Stock |
|
| 25MG | 93 | In Stock |
|
| 50MG | 146 | In Stock |
|
| 100MG | 228 | In Stock |
|
| 200MG | 340 | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameGSK3a-IN-38
-
NoteResearch use only, not for human use.
-
Brief DescriptionGSK3a-IN-38 is a novel small molecule compound that has inhibitory effects on GSK-3a.
-
DescriptionGSK3a-IN-38 is a novel small molecule compound that has inhibitory effects on GSK-3a.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayPI3K/Akt/mTOR signaling
-
TargetGSK-3
-
RecptorGSK-3
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1062138-03-7
-
Formula Weight308.38
-
Molecular FormulaC18H20N4O
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESO=C1C2=C(NC=3NN=C(C3C2C=4C=CN=CC4)C)CC(C)(C)C1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
molnova catalog
related products
-
Sulfaphenazole
Sulfaphenazole is an inhibitor of CYP2C9 (Ki: 0.3 μM) that demonstrates at least 100-fold selectivity over other CYP450 isoforms (Ki: 63/29 μM for CYP2C8/CYP2C18, respectively, and no activity at CYP1A1, CYP1A2, CYP3A4, CYP2C19).
-
AR-A014418
A potent, specific ATP-competitive inhibitor of GSK-3β with Ki/IC50 of 38/104 nM.
-
CCG 203769
CCG 203769 is a selective inhibitor of RGS4 with an IC50 of 17 nM for the RGS4-Gαo protein-protein interaction.
